Bioinspired IDO1-loaded Cu/ZIF for alopecia areata therapy via remodeling immune privilege
Preprint
- 1 October 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Alopecia areata (AA) is an autoimmune disease driven by the collapse of hair follicle immune privilege. Currently available treatments showed limited efficacy and high recurrence rates. Indoleamine 2,3-dioxygenase 1 (IDO1) has been recognized as critical enzyme by catalyzing tryptophan-to-kynurenine conversion to induce immunosuppression and maintain immune privilege. Aberrant IDO1 inactivation disrupts hair follicle immune privilege, causing inflammatory follicular damage and subsequent hair loss. Herein, we designed an IDO1-loaded Cu-doped zeolitic imidazolate framework (IDO@Cu/ZIF) to restore tryptophan-to-kynurenine metabolism, thereby rebuilding hair follicle immune privilege for long-term AA management. By mimicking the Cu/Zn centers in natural antioxidant enzymes, Cu/ZIF nanozymes deliver high capability to eliminate excessive reactive oxygen species in AA lesions. Meanwhile, Cu atom-induced upshift of the d-band center enhances substrate adsorption, thereby improving antioxidant performance. In vitro and in vivo experiments confirmed that IDO@Cu/ZIF reconstructs hair follicle immune privilege by restoring the tryptophan/kynurenine axis, thereby promoting hair follicle regeneration and achieving approximately 75% hair coverage. More importantly, IDO@Cu/ZIF treatment maintains long-term immune privilege and effectively suppresses AA recurrence. This study offers mechanistic insights into the rational design of high-performance antioxidant nanozymes and expands their potential applications in autoimmune diseases of AA.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Metal–Organic Framework Nanozymes: From Rational Design and Synthesis to Biomedical ApplicationsNano-Micro Letters, 2026
- Bimetallic Cu/Zn Single‐Atom Nanozyme with Superoxide Dismutase‐Like ActivitySmall, 2025
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of TreatmentAmerican Journal of Clinical Dermatology, 2025
- Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia AreataJAMA Dermatology, 2024
- Microneedle‐Mediated Delivery of Immunomodulators Restores Immune Privilege in Hair Follicles and Reverses Immune‐Mediated AlopeciaAdvanced Materials, 2024
- Bioinspired metal-organic framework nanozyme reinforced with thermosensitive hydrogel for regulating inflammatory responses in Parkinson’s diseaseNano Research, 2023
- Janus Kinase Inhibitors for Alopecia AreataJAMA Network Open, 2023
- Superoxide Dismutase‐like Activity of Zeolitic Imidazolate Framework Nanoparticles Comprising Biomimetic Imidazolato‐bridged CuZn UnitsChemistry – A European Journal, 2023
- Baricitinib for the Treatment of Alopecia AreataDrugs, 2023
- Multiwfn: A multifunctional wavefunction analyzerJournal of Computational Chemistry, 2011